狼疮性肾炎糖皮质激素治疗的最优策略
本综述深入分析狼疮性肾炎(LN)的糖皮质激素治疗,LN影响高达51.7%的系统性红斑狼疮患者,显著增加死亡和终末期肾病风险。综述讨论糖皮质激素使用的历史演变,从大剂量方案转向联合免疫抑制剂和较低糖皮质激素剂量以减少不良反应,并探讨静脉冲击和口服方案及低剂量/无糖皮质激素方案。结论强调需未来研究优化方案、细化减量方案并确定更安全的联合治疗。
要点
- LN影响高达51.7%的SLE患者,显著增加死亡和ESKD风险。
- 糖皮质激素治疗从大剂量转向联合免疫抑制剂和较低剂量以减少不良反应。
- 低剂量和无糖皮质激素方案有前景但需进一步研究。
核心结论
- 糖皮质激素仍是LN管理的基石,但需未来研究优化方案、细化减量方案并确定更安全的联合治疗。
研究设计与样本
- 本综述深入分析狼疮性肾炎的糖皮质激素治疗,涵盖历史演变、机制、给药策略和替代方案。
主要发现
- LN影响高达51.7%的SLE患者,显著增加死亡和终末期肾病风险。
- 糖皮质激素通过基因组和非基因组途径调节免疫和代谢,长期使用与感染、骨质疏松、高血糖和心血管疾病风险相关。
- 糖皮质激素使用从大剂量方案转向联合免疫抑制剂和较低剂量以减少不良反应。
关键数值与推荐
- LN影响高达51.7%的SLE患者。
临床怎么用
- 临床可考虑联合免疫抑制剂和较低糖皮质激素剂量以减少不良反应。
- 低剂量和无糖皮质激素方案有前景但需进一步研究。
局限性
- 低剂量和无糖皮质激素方案需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review provides an in-depth analysis of glucocorticoid therapy for lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus that affects up to 51.7% of patients. LN significantly increases the risk of mortality and progression to end-stage kidney disease. Glucocorticoids have been central to LN treatment for decades due to their anti-inflammatory properties, but optimal dosing strategies remain uncertain. The review discusses the historical evolution of glucocorticoid use, highlighting the shift from high-dose regimens to combined approaches with immunosuppressants and lower glucocorticoid doses to minimize adverse effects. Mechanistically, glucocorticoids exert effects through genomic and non-genomic pathways, modulating immune responses and metabolism. Long-term use is associated with risks such as infection, osteoporosis, hyperglycemia and cardiovascular disease. The review examines different dosing strategies, including intravenous pulse therapy and oral regimens, and presents evidence of their efficacy and safety. It also explores alternative approaches, such as low-dose and glucocorticoid-free regimens, which show promise but require further study. The review concludes by emphasizing the need for future research to optimize glucocorticoid regimens, refine tapering protocols and identify safer therapeutic combinations, as glucocorticoids remain a cornerstone in LN management despite their challenges.
引用
- Figueroa-Parra G, Bautista-Vargas M, Navarro-Mendoza E, et al. Optimal glucocorticoid therapy in lupus nephritis. Nephrol Dial Transplant. 2025. PMID: 39706677. doi:10.1093/ndt/gfae294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。